The prospects of the molecular targeted therapies for the head and neck cancer

• YANE Katsunari

  Department of Otorhinolaryngology, Nara Hospital, Kinki University School of Medicine

Bibliographic Information

Other Title

• 頭頸部癌に対する分子標的治療の展望について

Abstract

Blocking the EGFR and the VEGFR has emerged as primary strategies that account for the success of current targeted therapies in cancer. Recent studies with cetuximab, a monoclonal antibody inhibitor of the EGFR, have demonstrated survival benefits in advanced head and neck cancer, and it is the only targeted therapy approved for use by the US Food and Drug Administration (FDA). However, cetuximab is not yet approved in Japan, and a phase II study is carried out. The molecular target therapies of the head and neck region in Japan are far behind the world. Cetuximab should be approved early in Japan and those therapies in Japan must catch up with the world.

Journal

• jibi to rinsho

  jibi to rinsho 57 (Suppl.2), S171-S176, 2011

  JIBI TO RINSHO KAI

Keywords

• EGFR

Details

• CRID: 1390282679547348480
• NII Article ID: 130004862286
• NII Article ID: 50008036510
• DOI: 10.11334/jibi.57.s171
• ISSN: 21851034
• ISSN: 04477227
• Web Site: https://search.jamas.or.jp/link/ui/2012089222
• Text Lang: ja
• Data Source:
  • JaLC
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed